title: The impact of the Orphan Drug Act on drug discovery.
abstract: For nearly a quarter of a century the FDA Office of Orphan Products Development has administered the US Orphan Drug Act, which assists in bringing a wide variety of drug and biological (drug) products to treat rare diseases to market. Enthusiasm for rare disease product development has been sustained, seen throughout a wide spectrum of product types and disease conditions, and has resulted in clinically meaningful medical advances. Development of programmes for rare disease treatment worldwide, coupled with the development of drugs for diseases affecting developing countries, attests to the strength of this legislation. The marketing of almost 300 products in the US for rare diseases also testifies to the depth and intensity of scientific endeavour in this area.
authors.affiliation: Office of Orphan Products Development (HF-35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, US. Marlene.Haffner@FDA.HHS.Gov.
authors.forename: Marlene E
authors.initials: ME
authors.lastname: Haffner
authors.forename: Paul D
authors.initials: PD
authors.lastname: Maher